var data={"title":"Renal actions of dopamine","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Renal actions of dopamine</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/contributors\" class=\"contributor contributor_credentials\">Richard H Sterns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/contributors\" class=\"contributor contributor_credentials\">Michael Emmett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/contributors\" class=\"contributor contributor_credentials\">John P Forman, MD, MSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 31, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is synthesized within the kidney in the proximal tubule from circulating L-dopa, via the enzyme L-amino acid decarboxylase [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/1-3\" class=\"abstract_t\">1-3</a>]. There are also renal nerves that contain dopamine, although the physiologic significance of these nerves is unclear.</p><p>The renal actions of <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> are discussed here. The use of dopamine in patients with shock is presented elsewhere. (See <a href=\"topic.htm?path=use-of-vasopressors-and-inotropes\" class=\"medical medical_review\">&quot;Use of vasopressors and inotropes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">RENAL ACTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Circulating and locally formed <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> can affect both sodium excretion and renal hemodynamics via activation of the D1-like and D2-like receptors [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/1,4,5\" class=\"abstract_t\">1,4,5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Natriuresis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is a natriuretic hormone, increasing sodium excretion by diminishing reabsorption, primarily in the proximal tubule [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/1,2,6,7\" class=\"abstract_t\">1,2,6,7</a>]. This effect of dopamine appears to involve both of the steps involved in transtubular sodium transport:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a>, acting via the generation of cyclic AMP, decreases the activity of the Na-H exchanger in the luminal membrane, a transporter that plays an important role in the entry of filtered sodium into the cell [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> inhibits the Na-K-ATPase pump in the basolateral membrane [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/1,2,8\" class=\"abstract_t\">1,2,8</a>]. Sodium that has entered the cell from the lumen is normally transported by this pump out of the cell into the peritubular interstitium (and then the peritubular capillary).</p><p/><p>In addition to these proximal effects, <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> can also reduce sodium reabsorption in the collecting tubules. This response may be mediated both by decreased secretion of aldosterone [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/9\" class=\"abstract_t\">9</a>] and by diminished activity of the Na-K-ATPase pump in the renal tubular cells [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/10\" class=\"abstract_t\">10</a>]. The latter effect appears to be mediated by local prostaglandin generation [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/10\" class=\"abstract_t\">10</a>].</p><p>The natriuretic effects of <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> depend in part upon dietary sodium intake. During dietary sodium restriction, the ability of endogenous renal dopamine to inhibit sodium transport is abolished. In addition, intravenous dopamine or <a href=\"topic.htm?path=fenoldopam-drug-information\" class=\"drug drug_general\">fenoldopam</a> (a DA1 receptor agonist) induces natriuresis in subjects consuming a high-sodium diet but not a low-sodium diet. However, administration of an angiotensin-converting enzyme (ACE) inhibitor to individuals on a low-sodium diet restores the natriuretic properties of dopamine, suggesting an interaction between dopamine and the renin-angiotensin system [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Vasodilation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When infused in low doses (0.5 to 3 <span class=\"nowrap\">mcg/kg</span> per minute), <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> dilates the interlobular arteries and both the afferent (preglomerular) and efferent (postglomerular) arterioles [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/6,12\" class=\"abstract_t\">6,12</a>]. The net effect is a relatively large increase in renal blood flow with a lesser or no elevation in glomerular filtration rate (GFR) [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/7,13\" class=\"abstract_t\">7,13</a>]; the relative lack of increase in GFR is due to the efferent dilatation, which minimizes the rise in intraglomerular pressure. At higher concentrations (above 5 <span class=\"nowrap\">mcg/kg</span> per minute), however, dopamine induces renal vasoconstriction, a response that is mediated by activation of the alpha-adrenergic receptors [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/6,12,14\" class=\"abstract_t\">6,12,14</a>].</p><p>The increase in renal perfusion with low-dose <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> may not be seen in patients with acute tubular necrosis (ATN) [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=possible-prevention-and-therapy-of-ischemic-acute-tubular-necrosis\" class=\"medical medical_review\">&quot;Possible prevention and therapy of ischemic acute tubular necrosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Physiologic role</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although these actions can be readily demonstrated by intravenous infusion [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/7\" class=\"abstract_t\">7</a>], the physiologic importance of <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> remains to be defined. The local production of dopamine is increased by volume expansion [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/7,15\" class=\"abstract_t\">7,15</a>], a finding that is consistent with a role in the ensuing natriuresis. This response is mediated in part by increased activity of L-amino acid decarboxylase, the enzyme that converts L-dopa into dopamine [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/2\" class=\"abstract_t\">2</a>]. Also compatible with dopamine being a natriuretic hormone is the observation that administration of a dopamine receptor inhibitor to experimental animals impairs the response to modest volume expansion [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL UTILITY</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Postischemic acute tubular necrosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The previously mentioned findings have led to the use of low-dose, &quot;renal dose&quot; <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> both to increase the urine output and to preserve renal function in oliguric patients at risk for postischemic acute tubular necrosis (ATN). However, such therapy is ineffective and may cause harm, and therefore should <strong>not</strong> be used. This is discussed in detail separately. (See <a href=\"topic.htm?path=possible-prevention-and-therapy-of-ischemic-acute-tubular-necrosis\" class=\"medical medical_review\">&quot;Possible prevention and therapy of ischemic acute tubular necrosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Polyuria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is frequently administered to maintain the systemic blood pressure in hypotensive patients with sepsis. A rare complication in this setting is the development of a marked natriuresis and diuresis with the urine volume occasionally exceeding 300 to 500 <span class=\"nowrap\">mL/hour</span> despite reduced renal perfusion [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/17,18\" class=\"abstract_t\">17,18</a>]. The natriuresis presumably reflects the normal inhibitory effect of dopamine on sodium reabsorption; why it may be dramatically enhanced in some septic patients is not clear.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Resistant edema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of low-dose <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> in patients with diuretic-resistant edema is unclear. The best data come from the Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study in which 241 patients with acute heart failure and kidney dysfunction (estimated glomerular filtration rate [eGFR] of 15 to 60 <span class=\"nowrap\">mL/min/1</span>.73 m<sup>2</sup>) were randomly assigned to receive dopamine (2 <span class=\"nowrap\">microg/kg/min)</span> or placebo; all patients received diuretic therapy [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/4\" class=\"abstract_t\">4</a>]. Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (8524 versus 8296 mL) or on renal function measured by cystatin C level (0.12 versus 0.11) [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/4\" class=\"abstract_t\">4</a>].</p><p>In a post-hoc analysis of the ROSE study, the response to <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> was found to differ according to ejection fraction [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/5\" class=\"abstract_t\">5</a>]. Dopamine-enhanced urine volume and sodium excretion were greater among those with reduced ejection fractions (ie, &le;40 percent) than among those with preserved ejection fraction (ie, &gt;40 percent). However, the findings of this post-hoc analysis could be due to chance and require confirmation.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DOPAMINE A-1 AGONISTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is possible that the renal therapeutic actions of <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> are obviated because of its nonselective effects upon multiple dopaminergic and adrenergic receptors. For the treatment of acute renal failure, an ideal agent would selectively activate the renal dopamine A-1 receptor without affecting additional receptors, thereby lowering renal vascular resistance, enhancing natriuresis, and increasing urinary output [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/19\" class=\"abstract_t\">19</a>]. Although not ideal, <a href=\"topic.htm?path=fenoldopam-drug-information\" class=\"drug drug_general\">fenoldopam</a> is a relatively selective dopamine A-1 receptor agonist that increases sodium excretion and renal blood flow in normal and hypertensive humans [<a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Studies that have examined the utility of <a href=\"topic.htm?path=fenoldopam-drug-information\" class=\"drug drug_general\">fenoldopam</a> are discussed separately. (See <a href=\"topic.htm?path=possible-prevention-and-therapy-of-ischemic-acute-tubular-necrosis\" class=\"medical medical_review\">&quot;Possible prevention and therapy of ischemic acute tubular necrosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1812836\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is synthesized within the proximal tubule and is also released from renal nerves that contain dopamine. Circulating and locally formed dopamine can affect both sodium excretion and renal hemodynamics (see <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2\" class=\"local\">'Renal actions'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is a natriuretic hormone, increasing sodium excretion by diminishing reabsorption in the proximal tubule and collecting tubule. (See <a href=\"#H3\" class=\"local\">'Natriuresis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When infused in low doses (0.5 to 3 <span class=\"nowrap\">mcg/kg</span> per minute), <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> dilates the interlobular arteries and both the afferent (preglomerular) and efferent (postglomerular) arterioles. The net effect is a relatively large increase in renal blood flow with a lesser or no elevation in glomerular filtration rate (GFR). At higher concentrations (above 5 <span class=\"nowrap\">mcg/kg</span> per minute), dopamine induces renal vasoconstriction. (See <a href=\"#H4\" class=\"local\">'Vasodilation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low-dose (ie, &quot;renal dose&quot;) <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> has been used to increase the urine output and to preserve renal function in oliguric patients at risk for ischemic acute tubular necrosis (ATN). However, such therapy is ineffective and may cause harm, and therefore should <strong>not</strong> be used. This is discussed in detail separately. (See <a href=\"topic.htm?path=possible-prevention-and-therapy-of-ischemic-acute-tubular-necrosis#H10\" class=\"medical medical_review\">&quot;Possible prevention and therapy of ischemic acute tubular necrosis&quot;, section on 'Dopamine, fenoldopam, atrial natriuretic factor'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It has been proposed that the natriuretic and renal vasodilator activity of <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> can be used to potentiate the effect of diuretics in patients with resistant edema. However, limited data suggest that dopamine is not beneficial in these patients. (See <a href=\"#H9\" class=\"local\">'Resistant edema'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limited data suggest that <a href=\"topic.htm?path=fenoldopam-drug-information\" class=\"drug drug_general\">fenoldopam</a>, a selective <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> A-1 receptor agonist, may be beneficial in the prevention or treatment of acute kidney injury. These data, and corresponding recommendations, are discussed separately.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/1\" class=\"nounderline abstract_t\">Denton MD, Chertow GM, Brady HR. &quot;Renal-dose&quot; dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 50:4.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/2\" class=\"nounderline abstract_t\">Seri I, Kone BC, Gullans SR, et al. Influence of Na+ intake on dopamine-induced inhibition of renal cortical Na(+)-K(+)-ATPase. Am J Physiol 1990; 258:F52.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/3\" class=\"nounderline abstract_t\">Carey RM. Theodore Cooper Lecture: Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension 2001; 38:297.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/4\" class=\"nounderline abstract_t\">Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/5\" class=\"nounderline abstract_t\">Wan SH, Stevens SR, Borlaug BA, et al. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 2016; 9.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/6\" class=\"nounderline abstract_t\">Steinhausen M, Weis S, Fleming J, et al. Responses of in vivo renal microvessels to dopamine. Kidney Int 1986; 30:361.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/7\" class=\"nounderline abstract_t\">Olsen NV, Hansen JM, Ladefoged SD, et al. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin Sci (Lond) 1990; 78:503.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/8\" class=\"nounderline abstract_t\">Felder CC, Campbell T, Albrecht F, Jose PA. Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol 1990; 259:F297.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/9\" class=\"nounderline abstract_t\">Krishna GG, Danovitch GM, Beck FW, Sowers JR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med 1985; 105:214.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/10\" class=\"nounderline abstract_t\">Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89:1496.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/11\" class=\"nounderline abstract_t\">Natarajan AR, Eisner GM, Armando I, et al. The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans. J Am Soc Nephrol 2016; 27:265.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/12\" class=\"nounderline abstract_t\">Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med 1991; 115:153.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/13\" class=\"nounderline abstract_t\">Lauschke A, Teichgr&auml;ber UK, Frei U, Eckardt KU. 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69:1669.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/14\" class=\"nounderline abstract_t\">Thompson BT, Cockrill BA. Renal-dose dopamine: a siren song? Lancet 1994; 344:7.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/15\" class=\"nounderline abstract_t\">Alexander RW, Gill JR Jr, Yamabe H, et al. Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man. J Clin Invest 1974; 54:194.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/16\" class=\"nounderline abstract_t\">Hansell P, Fasching A. The effect of dopamine receptor blockade on natriuresis is dependent on the degree of hypervolemia. Kidney Int 1991; 39:253.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/17\" class=\"nounderline abstract_t\">Flis RS, Scoblionco DP, Bastl CP, Popovtzer MM. Dopamine-related polyuria in patients with gram-negative infection. Arch Intern Med 1977; 137:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/18\" class=\"nounderline abstract_t\">Polansky D, Eberhard N, McGrath R. Dopamine and polyuria. Ann Intern Med 1987; 107:941.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/19\" class=\"nounderline abstract_t\">Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998; 31:743.</a></li><li><a href=\"https://www.uptodate.com/contents/renal-actions-of-dopamine/abstract/20\" class=\"nounderline abstract_t\">Allison NL, Dubb JW, Ziemniak JA, et al. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987; 41:282.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2368 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1812836\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">RENAL ACTIONS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Natriuresis</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Vasodilation</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Physiologic role</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL UTILITY</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Postischemic acute tubular necrosis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Polyuria</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Resistant edema</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DOPAMINE A-1 AGONISTS</a></li><li><a href=\"#H1812836\" id=\"outline-link-H1812836\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=possible-prevention-and-therapy-of-ischemic-acute-tubular-necrosis\" class=\"medical medical_review\">Possible prevention and therapy of ischemic acute tubular necrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-vasopressors-and-inotropes\" class=\"medical medical_review\">Use of vasopressors and inotropes</a></li></ul></div></div>","javascript":null}